The FDA has approved the BLA for Ospomyv™ and Xbryk™, biosimilars to Prolia (denosumab) and Xgeva (denosumab), respectively.

Ospomyv, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Xbryk, a ...

Averto Medical, a clinical-stage medical device company pioneering minimally invasive gastrointestinal care, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted ...

The following article, which first appeared in The Post-Journal in May 2014, is an example of why there can more to a story ...

The following article, which first saw the light of day in May 2014, is an example of why there can more to a story than ...

KUALA LUMPUR, Malaysia, Feb. 25, 2025 /PRNewswire/ -- Medtronic plc, a global leader in healthcare technology, announced that ...

Shannin Desroches fought for a diagnosis after being dismissed. Now she tells PEOPLE that she's been given a 5% chance of ...

A family is preparing for three fundraising challenges in memory of their husband and dad who received treatment at an Oxford hospital.

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Samsung Bioepis announced FDA approval of Ospomyv and Xbryk, biosimilars referencing denosumab (Prolia, Xgeva).

The FDA approved the denosumab biosimilar Ospomyv, interchangeable with Prolia, for preventing osteoporosis-related fracture ...

"Woman," "elderly," and "disabled" were among a list of banned words reportedly circulating within the FDA, which the White ...